Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Language and Cognition01:27

Language and Cognition

Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

RMD open·2026
Same author

A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.

Kidney international·2026
Same author

Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data.

Lupus·2026
Same author

Systemic lupus erythematosus and associated organ damage in real-world settings: estimating damage scores using administrative claims data.

Clinical and experimental rheumatology·2026
Same author

Mobile Stroke Unit and Mechanical Thrombectomy Workflow: A Single Center 5-Year Experience.

Stroke (Hoboken, N.J.)·2026
Same author

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Current rheumatology reports·2025

Related Experiment Video

Updated: Jul 11, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Antiphospholipid syndrome and cognition.

Bernardo Liberato1, Roger A Levy

  • 1Neurology, Rede D'Or de Hospitais, Rio de Janeiro, Brazil.

Clinical Reviews in Allergy & Immunology
|October 6, 2007
PubMed
Summary

Antiphospholipid antibodies (aPL) contribute to neuropsychiatric issues beyond blood clots in antiphospholipid syndrome (APS). Research shows aPL causes inflammation and brain damage, leading to cognitive impairment and dementia.

Area of Science:

  • Neuroimmunology
  • Vascular Neurology
  • Rheumatology

Background:

  • Antiphospholipid syndrome (APS) is associated with neurologic events, primarily thrombotic occlusions.
  • A wider range of neuropsychiatric manifestations are linked to antiphospholipid antibodies (aPL).
  • The precise mechanisms driving aPL-related neurological dysfunction require further elucidation.

Purpose of the Study:

  • To explore the pathogenic role of aPL in neurological dysfunction.
  • To investigate the inflammatory pathways involved in aPL-related brain damage.
  • To clarify the contribution of aPL to cognitive impairment in APS.

Main Methods:

  • Experimental studies in mice models to assess the impact of aPL on neurological function.
  • Analysis of neuroimaging data to identify structural and metabolic brain changes.

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Related Experiment Videos

Last Updated: Jul 11, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

  • Review of clinical evidence linking aPL to cognitive deficits.

    • Main Results:

    • Experimental evidence indicates a pathogenic role for aPL, with inflammation as a key feature.
    • Neurological dysfunction appears to be both structurally destructive and functionally impairing.
    • Neuroimaging suggests micro-infarcts and metabolic impairments contribute to progressive dementia in aPL-positive individuals.

    Conclusions:

    • Antiphospholipid antibodies (aPL) play a direct role in causing neurological and cognitive damage.
    • Inflammation is a critical component of the pathogenic process initiated by aPL.
    • Distinguishing aPL-related cognitive impairment from other conditions like lupus is crucial for accurate diagnosis and management.